Subtopic Deep Dive
Chondrosarcoma Molecular Pathology
Research Guide
What is Chondrosarcoma Molecular Pathology?
Chondrosarcoma molecular pathology studies genetic alterations like IDH1/2 mutations, EXT1/2 changes, and hedgehog signaling driving cartilage tumor progression and therapy resistance.
This field analyzes genomic profiles correlating with histological grades in chondrosarcomas, the second most common primary bone malignancy. IDH1/2 mutations produce oncometabolite 2-hydroxyglutarate (2-HG), altering epigenetics (Li et al., 2015; 105 citations; Suijker et al., 2015; 102 citations). Over 10 papers from 2012-2023 detail these drivers, with ~800 combined citations.
Why It Matters
IDH1/2 mutations occur in 50-60% of conventional chondrosarcomas, enabling precision inhibitors like AGI-5198 to suppress 2-HG and tumorigenicity (Li et al., 2015). Src kinases mediate chemoresistance, where dasatinib sensitizes TP53-mutant cells to doxorubicin (van Oosterwijk et al., 2013). These findings support targeted therapies in surgery-resistant cases (Zając et al., 2021). FGFR3 deficiency upregulates hedgehog signaling, modeling chondroma progression (Zhou et al., 2015).
Key Research Challenges
IDH Inhibitor Efficacy Limits
Mutant IDH1 inhibitors reduce 2-HG but fail to block chondrosarcoma cell tumorigenicity (Suijker et al., 2015). AGI-5198 suppresses activity in some lines yet lacks broad efficacy (Li et al., 2015). Clinical translation stalls due to heterogeneous responses.
Epigenetic Mechanism Variability
IDH mutations hypermethylate histones without altering 5-hmC or outcome predictors in central chondrosarcomas (Cleven et al., 2017). Gene-specific histone changes dysregulate mesenchymal differentiation (Jin et al., 2015). Challenges persist in linking mutations to progression.
Chemoresistance Pathways
Src kinases drive doxorubicin resistance in TP53-mutant cells, reversed by dasatinib (van Oosterwijk et al., 2013). Stem/progenitor cell roles amplify therapeutic resistance (Boehme et al., 2018). Multi-driver interactions complicate targeting.
Essential Papers
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Luyuan Li, Ana C. Paz, Breelyn A. Wilky et al. · 2015 · PLoS ONE · 105 citations
Chondrosarcomas are malignant bone tumors that produce cartilaginous matrix. Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers including chondrosarco...
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
Johnny Suijker, Jan Oosting, Annemarie Koornneef et al. · 2015 · Oncotarget · 102 citations
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found in a subset of benign and malignant cartilage tumors, gliomas and leukaemias. The mutant enzyme causes the production of D-2-hydrox...
Chondrosarcoma: A Clinical Review
Aaron Gazendam, Snežana Popović, Naveen Parasu et al. · 2023 · Journal of Clinical Medicine · 86 citations
Chondrosarcomas are a diverse group of malignant cartilaginous matrix-producing neoplasms. Conventional chondrosarcomas are a continuum of disease based on the biologic activity of the tumor. The t...
Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance
Karen A. Boehme, Sabine Schleicher, Frank Traub et al. · 2018 · International Journal of Molecular Sciences · 74 citations
Unlike other malignant bone tumors including osteosarcomas and Ewing sarcomas with a peak incidence in adolescents and young adults, conventional and dedifferentiated chondrosarcomas mainly affect ...
H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach
Thibault Kervarrec, Christine Collin, Fréderique Larousserie et al. · 2017 · Modern Pathology · 73 citations
Chondrosarcoma-from Molecular Pathology to Novel Therapies
Agnieszka Zając, Sylwia Kopeć, Bartłomiej Szostakowski et al. · 2021 · Cancers · 73 citations
Chondrosarcoma (CHS) is the second most common primary malignant bone sarcoma. Overall survival and prognosis of this tumor are various and often extreme, depending on histological grade and tumor ...
Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes
Yonghui Jin, Hassan Elalaf, Makoto Watanabe et al. · 2015 · PLoS ONE · 65 citations
Somatic mutations in the isocitrate dehydrogenase (IDH)1/2 genes endow encoding proteins with neomorphic activity to produce the potential oncometabolite, 2-hydroxyglutarate (2-HG), which induces t...
Reading Guide
Foundational Papers
van Oosterwijk et al. (2013; British Journal of Cancer, 64 citations) establishes Src-dasatinib in chemoresistance. van Oosterwijk et al. (2012) provides grade III/dedifferentiated cell lines for molecular studies.
Recent Advances
Gazendam et al. (2023; 86 citations) reviews clinical-molecular spectrum. Zając et al. (2021; 73 citations) links pathology to therapies. Boehme et al. (2018; 74 citations) details stem/progenitor resistance.
Core Methods
IDH1/2 sequencing with 2-HG quantification (Li et al., 2015). Histone IHC (H3K4me3, H3K27me3; Cleven et al., 2017). FGFR3 knockout models for hedgehog (Zhou et al., 2015). Src inhibitor assays (van Oosterwijk et al., 2013).
How PapersFlow Helps You Research Chondrosarcoma Molecular Pathology
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to find IDH1/2 mutation papers, then citationGraph on Li et al. (2015; 105 citations) reveals 50+ citing works on chondrosarcoma inhibitors. findSimilarPapers expands to hedgehog signaling like Zhou et al. (2015).
Analyze & Verify
Analysis Agent applies readPaperContent to extract 2-HG levels from Suijker et al. (2015), verifies claims via CoVe against Cleven et al. (2017), and runs PythonAnalysis on mutation frequencies with pandas for statistical correlations (e.g., IDH prevalence by grade). GRADE scores evidence as high for IDH drivers.
Synthesize & Write
Synthesis Agent detects gaps in IDH therapy translation post-Li et al. (2015), flags contradictions between inhibitor studies. Writing Agent uses latexEditText, latexSyncCitations for van Oosterwijk et al. (2013), and latexCompile to generate review sections with exportMermaid for Src-IDH pathway diagrams.
Use Cases
"Analyze IDH1 mutation frequency and 2-HG impact across chondrosarcoma grades."
Research Agent → searchPapers('IDH1 chondrosarcoma') → Analysis Agent → readPaperContent(Li 2015, Suijker 2015) → runPythonAnalysis(pandas aggregate mutation rates, matplotlib grade plots) → GRADE report with statistical p-values.
"Draft LaTeX review on Src kinase chemoresistance in chondrosarcoma."
Research Agent → citationGraph(van Oosterwijk 2013) → Synthesis Agent → gap detection → Writing Agent → latexEditText('dasatinib doxorubicin synergy'), latexSyncCitations(64 cites), latexCompile → peer-ready PDF.
"Find GitHub repos implementing chondrosarcoma IDH simulation models."
Research Agent → searchPapers('IDH chondrosarcoma model') → Code Discovery → paperExtractUrls → paperFindGithubRepo(Zhou 2015 hedgehog) → githubRepoInspect → runnable Python code for FGFR3-hedgehog analysis.
Automated Workflows
Deep Research workflow scans 50+ chondrosarcoma papers via searchPapers, structures IDH/EXT1 reports with GRADE grading. DeepScan's 7-steps verify mutation-outcome links from Cleven et al. (2017) using CoVe checkpoints. Theorizer generates hypotheses on IDH-Src interactions from van Oosterwijk et al. (2013) and Boehme et al. (2018).
Frequently Asked Questions
What defines chondrosarcoma molecular pathology?
It examines IDH1/2 mutations producing 2-HG, EXT1/2 alterations, and hedgehog signaling in cartilage tumor progression (Li et al., 2015). Focuses on genomic-histological correlations for grading.
What are key methods in this field?
High-resolution melting, pyrosequencing for H3F3/IDH detection (Kervarrec et al., 2017). Cell line assays test inhibitors like AGI-5198 (Li et al., 2015). Histone modification IHC assesses epigenetic changes (Cleven et al., 2017).
Name top papers on IDH in chondrosarcoma.
Li et al. (2015; PLoS ONE, 105 citations) shows AGI-5198 suppresses tumorigenicity. Suijker et al. (2015; Oncotarget, 102 citations) finds no tumorigenic block despite 2-HG drop. Cleven et al. (2017) rules out outcome prediction.
What open problems exist?
IDH inhibitors lack broad anti-tumor effects (Suijker et al., 2015). Chemoresistance via Src/TP53 needs multi-target strategies (van Oosterwijk et al., 2013). Stem cell roles in late-onset tumors unresolved (Boehme et al., 2018).
Research Bone Tumor Diagnosis and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chondrosarcoma Molecular Pathology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers